Pretomanid Drug Asset Due Diligence Report 2026

This Pretomanid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pretomanid can convert its Small molecule drug profile and CYP2C19 x CYP2C8 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pretomanid (query alias: pretomanid)
Modality / target	Small molecule drug; CYP2C19 x CYP2C8; CYP2C19 inhibitors, CYP2C8 inhibitors, Cell wall inhibitors
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	Mylan IRE Healthcare Ltd., Mylan Ireland Ltd., Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

The MCP disease footprint includes Drug-Resistant Tuberculosis, Multidrug resistant pulmonary tuberculosis, Tuberculosis, Multidrug-Resistant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07517445	Phase 2	Recruiting	165	Bactericidal Activity
NCT07525427	Phase 2	Recruiting	150	Bactericidal Activity
NCT07672405	Phase 2	Recruiting	100	Incidence and characterization of treatment-emergent adverse events (TEAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Phase 2; n=309; evaluation: not stated. Reported fields: Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.593 proportion of participants (95% Confidence Interval, 0.472 - 0.718); Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.476 proportion of participants (95% Confidence Interval, 0.362 - 0.606); -

A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis

Phase 2; n=93; evaluation: not stated. Reported fields: -; ≥ Grade 3 TEAEs At Week 19 = 16.7 percentage of participants ; -

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe

Phase 2; n=94; evaluation: Positive. Reported fields: AE = The most common AEs were gastrointestinal, and the most common SAEs were related to the nervous and gastrointestinal systems. There were no deaths reported during the study. ; AE = The most common AEs were gastrointestinal, and the most common SAEs were related to the nervous and gastrointestinal systems. There were no deaths reported during the study.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pretomanid addresses Drug-Resistant Tuberculosis, Multidrug resistant pulmonary tuberculosis, Tuberculosis, Multidrug-Resistant. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-08-10	TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan	Approved	Financial terms not disclosed
2023-01-18	Viatris Korea joins forces with TB Alliance for global distribution of Dovprela, a treatment for tuberculosis.	Approved	Financial terms not disclosed
2021-09-06	TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pretomanid amorphous form”. The milestone feed surfaced a patent-application signal described as “Preparation method and application of antituberculous drug Pretomanid”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO